XTalks

JUNE 17, 2024

Hugel, a Korean medical aesthetics company, recently announced that it has received marketing approval from the US Food and Drug Administration (FDA) for its botulinum toxin, Letybo (letibotulinumtoxinA-wlbg), for the treatment of glabellar lines. We are thrilled with the FDA’s approval of Letybo. 134 How Does Letybo Work?

FDA Approval 52

FDA Approval Marketing Botox Clinical Trials 52

pharmaphorum

FEBRUARY 12, 2021

The life sciences industry has an important role in the Irish economy, with sectors such as biologics booming across the country. With an attractive corporate tax rate and the youngest workforce in the EU, Ireland continues to be a popular destination for life science companies to settle.

Life Science 124

Life Science Botox Pharma Packaging Regulation 124

The Pharma Data

AUGUST 1, 2021

Global Botox Therapeutic net revenues were $603 million, an increase of over 100.0 Global Botox Cosmetic net revenues were $584 million, an increase of over 100.0 The FDA cited its ongoing review of Pfizer’s post-marketing study, ORAL Surveillance, evaluating tofacitinib in patients with rheumatoid arthritis (RA).

Botox 52

Botox Cosmetics Trials Clinical Trials 52

XTalks

JULY 4, 2024

We will also examine the rising stars like Novo Nordisk’s Ozempic (semaglutide), which has become a frontrunner in diabetes management, and the dynamic performance of Gilead Sciences’ Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) in the HIV treatment landscape.

Sales 52

Sales Drugs FDA Approval Marketing 52

XTalks

NOVEMBER 1, 2024

The neurology drug market continues to be dynamic with novel treatments that cater to a broad range of neurological and psychiatric conditions. In 2024, several blockbuster neurology medications are set to lead the market, capturing the attention of healthcare professionals, investors and patients alike. as of January 2024.

FDA Approval 79

FDA Approval Drugs Botox Sales 79

XTalks

AUGUST 2, 2023

Join us as we present an in-depth analysis of each company’s revenue, net income, R&D investments, core therapeutic areas, market presence and strategic collaborations. is a global pharmaceutical company, working across both developed and emerging markets. 2022 Revenue: Pfizer reported an annual revenue of $100.33 Pfizer Inc.

Sales 85

Sales Manufacturing FDA Approval Life Science 85